We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+57.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.59B
AUM Growth
+$852M
Cap. Flow
-$15.9M
Cap. Flow %
-0.44%
Top 10 Hldgs %
60.96%
Holding
76
New
4
Increased
9
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$66.4M
2
JANX icon
Janux Therapeutics
JANX
+$33.7M
3
RVMD icon
Revolution Medicines
RVMD
+$31.9M
4
PVLA
Palvella Therapeutics
PVLA
+$11.8M
5
ALLK
Allakos
ALLK
+$11.7M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$45.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$44M
3
IMVT icon
Immunovant
IMVT
+$39.7M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$37M
5
MRUS
Merus
MRUS
+$30.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.62B
$1.11B 30.92%
21,751,284
– –
RVMD icon
2
Revolution Medicines
RVMD
$40.9B
$167M 4.66%
6,255,588
+1,300,000
+26% +$31.9M
AXSM icon
3
Axsome Therapeutics
AXSM
$12.1B
$153M 4.27%
2,131,100
– –
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.5B
$134M 3.72%
5,683,489
+3,228,400
+131% +$66.4M
IONS icon
5
Ionis Pharmaceuticals
IONS
$8.85B
$117M 3.25%
2,846,015
+285,254
+11% +$11M
GHRS icon
6
GH Research
GHRS
$1.95B
$110M 3.07%
9,275,158
– –
KYMR icon
7
Kymera Therapeutics
KYMR
$8.8B
$109M 3.04%
4,739,004
– –
PTGX icon
8
Protagonist Therapeutics
PTGX
$8.92B
$104M 2.91%
3,775,900
– –
PNT
9
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$95.7M 2.67%
10,563,748
– –
LKFT
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$88M 2.45%
2,165,109
– –
RPTX
11
DELISTED
Repare Therapeutics
RPTX
$87.7M 2.45%
8,291,988
– –
GPCR icon
12
Structure Therapeutics
GPCR
$3.52B
$72.7M 2.03%
1,750,000
– –
FDMT icon
13
4D Molecular Therapeutics
FDMT
$526M
$72.4M 2.02%
4,007,413
– –
KURA icon
14
Kura Oncology
KURA
$826M
$71.2M 1.98%
6,730,983
– –
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.2B
$70.4M 1.96%
1,827,958
– –
OLMA icon
16
Olema Pharmaceuticals
OLMA
$1.03B
$68.7M 1.92%
7,611,503
– –
XOMA
17
DELISTED
Xoma
XOMA
$68.6M 1.91%
3,633,743
– –
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$58.3M 1.63%
9,423,215
– –
ZYME icon
19
Zymeworks
ZYME
$1.67B
$50.7M 1.41%
5,870,000
– –
REPL icon
20
Replimune Group
REPL
$49.8M 1.39%
2,143,036
– –
JANX icon
21
Janux Therapeutics
JANX
$950M
$48.7M 1.36%
4,106,945
+2,521,268
+159% +$33.7M
TYRA icon
22
Tyra Biosciences
TYRA
$1.97B
$46.7M 1.3%
2,739,595
-500,000
-15% -$7.25M
LXRX icon
23
Lexicon Pharmaceuticals
LXRX
$1.04B
$45.8M 1.28%
19,995,332
+3,846,153
+24% +$10.2M
MRUS
24
DELISTED
Merus
MRUS
$42.2M 1.18%
1,602,420
-1,376,000
-46% -$30.1M
RLAY icon
25
Relay Therapeutics
RLAY
$4.24B
$39.2M 1.09%
3,120,521
– –
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2023 Portfolio in Review

As of Q2 2023, BVF Inc held 76 positions worth $3.59B, up 31% from $2.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc's Q2 2023 filing shows 4 new, 9 increased, 2 reduced and 9 closed positions. Its largest new stake was TScan Therapeutics: 2,989,474 shares worth $7.47M. The largest sale was Syndax Pharmaceuticals, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BVF Inc's largest Q2 2023 buy was TScan Therapeutics: 2,989,474 shares worth $7.47M.
  • BVF Inc added most to IDEAYA Biosciences in Q2 2023, an estimated $66.4M increase.
  • BVF Inc's biggest Q2 2023 reduction was Merus, cutting an estimated $30.1M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2023, selling an estimated $45.3M.
  • BVF Inc's ten largest holdings make up 61% of its $3.59B portfolio in Q2 2023.
  • BVF Inc opened 4 new positions and closed 9 in Q2 2023.
  • BVF Inc's portfolio value rose 31% quarter-over-quarter to $3.59B.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.